SYRE
Spyre Therapeutics, Inc.$90.65-0.17 (-0.19%)Prev Close$90.80·MCap$7.73B·P/E—·Vol512.7K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
26
$435.97M
◆
Net Activity
Net Seller
$435.97M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Spyre Therapeutics, Inc. (SYRE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 26 insider sales totaling $435.97M. The most recent insider transaction was by Burrows Scott L (officer: Chief Financial Officer), who sold $2.28M worth of shares on Sep 3, 2026. Spyre Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $7.73B.
SYRE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 25,732 | $88.75 | $2.28M | 104,594 |
| Sep 3, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $87.29 | $1.31M | 565,040 |
| Sep 3, 2026 | King-Jones Heidy | officer: See Remarks | Sell | 28,399 | $87.35 | $2.48M | 25,999-52% |
| Aug 10, 2026 | Albers Jeffrey W. | director | Sell | 23,000 | $104.53 | $2.40M | 19,360-54% |
| Aug 5, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $95.57 | $716.8K | 100,394 |
| Aug 5, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $95.51 | $1.43M | 581,740 |
| Jul 2, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $87.74 | $658.0K | 99,719 |
| Jul 2, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 8,334 | $87.70 | $730.9K | 1,834-82% |
| Jul 2, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $87.69 | $1.32M | 587,364 |
| Jun 26, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 15,000 | $87.13 | $1.31M | 107,994 |
| Jun 23, 2026 | HENDERSON MICHAEL THOMAS | director | Sell | 20,000 | $100.00 | $2.00M | 68,606 |
| Jun 23, 2026 | Fairmount Funds Management LLC | director | Sell | 4,684,781 | $85.31 | $399.66M7.8% OS | 0Exit |
| Jun 3, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $70.43 | $1.06M | 608,983 |
| Jun 3, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $71.06 | $532.9K | 103,693 |
| Jun 3, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 8,333 | $75.00 | $625.0K | 0Exit |
| May 8, 2026 | HENDERSON MICHAEL THOMAS | director | Sell | 80,000 | $74.40 | $5.95M | 166,202-32% |
| May 1, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 12,500 | $71.37 | $892.1K | 97,994 |
| May 1, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 78,333 | $71.50 | $5.60M | 57,027-58% |
| May 1, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $71.37 | $1.07M | 622,240 |
| Apr 3, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $49.34 | $370.1K | 99,294 |
| Apr 3, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 7,958 | $50.00 | $397.9K | 0Exit |
| Apr 3, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $49.33 | $739.9K | 630,196 |
| Feb 2, 2026 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $32.80 | $492.0K | 0 |
| Jan 2, 2026 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $30.68 | $460.1K | 0 |
| Dec 1, 2025 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $29.02 | $435.4K | 0 |
| Nov 3, 2025 | Turtle Cameron | Chief Executive Officer | Sell | 45,000 | $23.33 | $1.05M | 0 |
| Sep 2, 2025 | Burrows Scott L | Chief Financial Officer | Sell | 18,428 | $16.26 | $299.6K | 0 |
| Nov 8, 2024 | Albers Jeffrey W. | Director | Sell | 6,700 | $36.76 | $246.3K | 27,360 |
| Oct 28, 2024 | Albers Jeffrey W. | Director | Sell | 300 | $36.43 | $10.9K | 34,060 |
| Sep 5, 2024 | Burrows Scott L | Chief Financial Officer | Sell | 18,531 | $28.17 | $522.1K | 116,422 |
| Aug 25, 2022 | Souza Marcio | Director | Buy | 90,000 | $0.56 | $50.5K | 90,000 |
| Jun 10, 2022 | Hanley Jr. Michael Conick | Chief Commercial Officer | Buy | 28,200 | $0.71 | $20.0K | 36,200+353% |
| Mar 18, 2022 | Quinn Anthony G. | President & CEO | Buy | 80,079 | $2.34 | $187.7K | 550,540 |
| Mar 15, 2022 | Alspaugh Jonathan | Chief Financial Officer | Buy | 75,000 | $2.08 | $156.0K | 165,372+83% |
| Mar 15, 2022 | Quinn Anthony G. | President & CEO | Buy | 144,666 | $1.94 | $280.9K | 473,461+44% |
| Dec 13, 2021 | Alspaugh Jonathan | Chief Financial Officer | Buy | 50,000 | $3.72 | $186.0K | 90,372+124% |
| Dec 13, 2021 | Quinn Anthony G. | President & CEO | Buy | 53,634 | $3.71 | $199.0K | 328,795 |
| Dec 13, 2021 | Shanafelt Armen | Director | Buy | 150,000 | $3.66 | $549.7K | 150,000 |
| Aug 18, 2021 | Alspaugh Jonathan | Chief Financial Officer | Buy | 40,372 | $6.51 | $262.7K | 40,372 |
SYRE Insider Buying Activity
The following table shows recent insider purchases of Spyre Therapeutics, Inc. (SYRE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 25, 2022 | Souza Marcio | Director | Buy | 90,000 | $0.56 | $50.5K | 90,000 |
| Jun 10, 2022 | Hanley Jr. Michael Conick | Chief Commercial Officer | Buy | 28,200 | $0.71 | $20.0K | 36,200+353% |
| Mar 18, 2022 | Quinn Anthony G. | President & CEO | Buy | 80,079 | $2.34 | $187.7K | 550,540 |
| Mar 15, 2022 | Alspaugh Jonathan | Chief Financial Officer | Buy | 75,000 | $2.08 | $156.0K | 165,372+83% |
| Mar 15, 2022 | Quinn Anthony G. | President & CEO | Buy | 144,666 | $1.94 | $280.9K | 473,461+44% |
| Dec 13, 2021 | Alspaugh Jonathan | Chief Financial Officer | Buy | 50,000 | $3.72 | $186.0K | 90,372+124% |
| Dec 13, 2021 | Quinn Anthony G. | President & CEO | Buy | 53,634 | $3.71 | $199.0K | 328,795 |
| Dec 13, 2021 | Shanafelt Armen | Director | Buy | 150,000 | $3.66 | $549.7K | 150,000 |
| Aug 18, 2021 | Alspaugh Jonathan | Chief Financial Officer | Buy | 40,372 | $6.51 | $262.7K | 40,372 |
SYRE Insider Selling Activity
The following table shows recent insider sales of Spyre Therapeutics, Inc. (SYRE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 25,732 | $88.75 | $2.28M | 104,594 |
| Sep 3, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $87.29 | $1.31M | 565,040 |
| Sep 3, 2026 | King-Jones Heidy | officer: See Remarks | Sell | 28,399 | $87.35 | $2.48M | 25,999-52% |
| Aug 10, 2026 | Albers Jeffrey W. | director | Sell | 23,000 | $104.53 | $2.40M | 19,360-54% |
| Aug 5, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $95.57 | $716.8K | 100,394 |
| Aug 5, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $95.51 | $1.43M | 581,740 |
| Jul 2, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $87.74 | $658.0K | 99,719 |
| Jul 2, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 8,334 | $87.70 | $730.9K | 1,834-82% |
| Jul 2, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $87.69 | $1.32M | 587,364 |
| Jun 26, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 15,000 | $87.13 | $1.31M | 107,994 |
| Jun 23, 2026 | HENDERSON MICHAEL THOMAS | director | Sell | 20,000 | $100.00 | $2.00M | 68,606 |
| Jun 23, 2026 | Fairmount Funds Management LLC | director | Sell | 4,684,781 | $85.31 | $399.66M7.8% OS | 0Exit |
| Jun 3, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $70.43 | $1.06M | 608,983 |
| Jun 3, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $71.06 | $532.9K | 103,693 |
| Jun 3, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 8,333 | $75.00 | $625.0K | 0Exit |
| May 8, 2026 | HENDERSON MICHAEL THOMAS | director | Sell | 80,000 | $74.40 | $5.95M | 166,202-32% |
| May 1, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 12,500 | $71.37 | $892.1K | 97,994 |
| May 1, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 78,333 | $71.50 | $5.60M | 57,027-58% |
| May 1, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $71.37 | $1.07M | 622,240 |
| Apr 3, 2026 | Burrows Scott L | officer: Chief Financial Officer | Sell | 7,500 | $49.34 | $370.1K | 99,294 |
| Apr 3, 2026 | Sloan Sheldon | officer: Chief Medical Officer | Sell | 7,958 | $50.00 | $397.9K | 0Exit |
| Apr 3, 2026 | Turtle Cameron | director, officer: Chief Executive Officer | Sell | 15,000 | $49.33 | $739.9K | 630,196 |
| Feb 2, 2026 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $32.80 | $492.0K | 0 |
| Jan 2, 2026 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $30.68 | $460.1K | 0 |
| Dec 1, 2025 | Turtle Cameron | Chief Executive Officer | Sell | 15,000 | $29.02 | $435.4K | 0 |
| Nov 3, 2025 | Turtle Cameron | Chief Executive Officer | Sell | 45,000 | $23.33 | $1.05M | 0 |
| Sep 2, 2025 | Burrows Scott L | Chief Financial Officer | Sell | 18,428 | $16.26 | $299.6K | 0 |
| Nov 8, 2024 | Albers Jeffrey W. | Director | Sell | 6,700 | $36.76 | $246.3K | 27,360 |
| Oct 28, 2024 | Albers Jeffrey W. | Director | Sell | 300 | $36.43 | $10.9K | 34,060 |
| Sep 5, 2024 | Burrows Scott L | Chief Financial Officer | Sell | 18,531 | $28.17 | $522.1K | 116,422 |
SYRE Insiders
Similar Stocks to SYRE
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B